María José Agustín

ORCID: 0000-0003-0450-4196
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HER2/EGFR in Cancer Research
  • Chronic Lymphocytic Leukemia Research
  • Peptidase Inhibition and Analysis
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Diagnosis and Treatment
  • Cancer Treatment and Pharmacology
  • Pharmaceutical studies and practices
  • Lymphoma Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Neutropenia and Cancer Infections
  • Multiple and Secondary Primary Cancers
  • Medication Adherence and Compliance
  • Colorectal and Anal Carcinomas
  • Childhood Cancer Survivors' Quality of Life
  • Global Cancer Incidence and Screening
  • Cancer Risks and Factors
  • Neuroendocrine Tumor Research Advances
  • Head and Neck Cancer Studies
  • Economic and Financial Impacts of Cancer
  • Immune Cell Function and Interaction
  • Lung Cancer Treatments and Mutations

Hospital Universitario Miguel Servet
2007-2022

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene is gaining importance to be able predict fluoropyrimidine-associated toxicity. The aim of this project was describe frequency DPYD variants DPYD*2A (rs3918290); c.1679T>G (rs55886062); c.2846A>T (rs67376798) and c.1129-5923C>G (rs75017182; HapB3) Spanish oncological patients.Cross-sectional multicentric study (PhotoDPYD study) conducted hospitals located Spain designed register most relevant genetic patients. All...

10.1093/oncolo/oyad077 article EN cc-by-nc The Oncologist 2023-04-04

The contribution of the T cell-related inhibitory checkpoint PD-1 to regulation NK cell activity is still not clear with contradictory results concerning its expression and role in modulation cytotoxicity. We provide novel key findings on mechanism involved membrane functional consequences for elimination cancer cells. In contrast freshly isolated cells from patients, those healthy donors did express membrane. However, when were incubated tumor target cells, increased, concurrent CD107a...

10.1080/2162402x.2022.2096359 article EN cc-by-nc OncoImmunology 2022-07-06

ObjectiveTo explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for treatment selection active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse, condition that mainly afflicts older adults.MethodsA discrete choice experiment (DCE) was conducted among haematologists pharmacists. A literature review a focus group informed DCE design. CLL settings were defined by seven attributes: four patient/disease-related attributes (age,...

10.1016/j.jgo.2019.03.010 article EN cc-by-nc-nd Journal of Geriatric Oncology 2019-04-03

Evaluar la incidencia de cardiotoxicidad asociada al tratamiento con trastuzumab en práctica clínica asistencial, describiendo sus características, su manejo y los factores riesgo asociados. Estudio observacional retrospectivo que incluyó a pacientes cáncer mama HER-2 positivo durante el primer trimestre 2007 un hospital tercer nivel. Se realizó seguimiento desde inicio del hasta finales marzo 2008. Las fuentes datos utilizadas fueron programa informático oncología servicio farmacia,...

10.1016/s1130-6343(09)72165-8 article ES cc-by-nc-nd Farmacia Hospitalaria 2009-07-01

Objective The purpose of this study was to analyse the effectiveness and safety first-line treatment metastatic colorectal cancer (CRCm) in older patients treated a tertiary hospital. Material methods This an observational retrospective study, including aged 75 years or older, with CRCm, who received chemotherapy 2017. main variables studied were type treatment, Progression-Free Survival (PFS), Overall (OS), dose reductions, delays due adverse events. Results A total 59 (71.2% men) median...

10.1177/1078155220984229 article EN Journal of Oncology Pharmacy Practice 2021-01-11
Coming Soon ...